Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...

Group 1 - Kuehn Law is investigating potential claims related to proposed mergers involving Agile Therapeutics, Spirit AeroSystems, and Envestnet to ensure shareholder value maximization and fair processes [1] - Agile Therapeutics will be acquired by Insud Pharma for $1.52 per share in cash [1] - Spirit AeroSystems will sell to Boeing Co. with shareholders receiving $37.25 per share in Boeing common stock [1] - Envestnet will merge with Bain Capital for $63.15 per share in cash [1] Group 2 - UMB Financial Corporation will acquire Heartland Financial USA Inc. in an all-stock deal valued at approximately $2.0 billion [2] - The merger is positioned as a significant event for shareholders, emphasizing the importance of their participation in maintaining market integrity [2] Group 3 - Kuehn Law encourages concerned shareholders to contact them for involvement in safeguarding shareholder interests, with no costs incurred by the investors [3] - Shareholders are advised to act promptly due to the time-sensitive nature of legal rights [3]

Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE NEWSW ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 (609) 683-1880 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) ...

[Q1 2024 Performance Highlights](index=1&type=section&id=Q1%202024%20Performance%20Highlights) Agile Therapeutics reported strong Q1 2024 growth, with net revenue up 50% to $5.7 million, driven by Twirla demand and reduced operating costs Q1 2024 Key Performance Metrics | Metric | Q1 2024 | vs. Q4 2023 | vs. Q1 2023 | | :--- | :--- | :--- | :--- | | **Net Revenue ($ million)** | $5.7 | +58% | +50% | | **Twirla Demand (Total Cycles)** | 81,088 | +18% | +80% | | **Twirla Factory Sales (Total Cycles)** | 70,662 | +3% | +63% | | **Operating Expenses ($ million)** | $6.8 | +24% | -20% | - The increase in Q1 2024 net revenue was primarily attributed to higher demand for Twirla[3](index=3&type=chunk) - The company's growth strategy focuses on its five-state concentration, expanding its telemedicine reach, and strengthening relationships with planned parenthood organizations[2](index=2&type=chunk) [Q1 2024 Financial Results](index=2&type=section&id=Q1%202024%20Financial%20Results) Agile Therapeutics achieved a Q1 2024 GAAP net income of $1.3 million, a significant turnaround from the prior year's loss, supported by revenue growth Q1 2024 Key Financial Data | Financial Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | **Net Revenue ($ million)** | $5.7 | $3.8 | | **Cost of Goods Sold (COGS) ($ million)** | $1.7 | $2.0 | | **Total Operating Expenses ($ million)** | $6.8 | $8.5 | | **GAAP Net Income (Loss) ($ million)** | $1.3 | ($5.4) | | **GAAP EPS (basic and diluted)** | $0.28 | ($5.91) | | **Non-GAAP Net Loss ($ million)** | ($2.9) | ($7.1) | | **Non-GAAP Net Loss Per Share** | ($0.63) | ($7.76) | - Cash and cash equivalents were **$2.6 million** as of March 31, 2024, slightly up from **$2.5 million** at the end of 2023[7](index=7&type=chunk) - As of March 31, 2024, the company had **6,856,229 shares** of common stock outstanding[7](index=7&type=chunk) [Corporate Updates and Business Outlook](index=2&type=section&id=Corporate%20Updates%20and%20Business%20Outlook) Agile Therapeutics' stock moved to OTC in March 2024, with optimism for growth from new guidance expanding no-cost contraceptive access for women - As of March 26, 2024, the company's common stock is trading on the **OTC market** under its existing **AGRX** symbol[7](index=7&type=chunk) - The company is optimistic about new guidance from the Biden-Harris Administration announced in January 2024, which aims to expand access to FDA-approved contraceptives like Twirla at no cost for an estimated **49 million women**[7](index=7&type=chunk) - Management plans to explore all strategic opportunities, both internal and external, to advance Twirla's growth and increase shareholder value[2](index=2&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) The financial statements detail Q1 2024 performance, showing reduced stockholders' deficit and GAAP profitability, with non-GAAP reconciliation provided [Balance Sheets](index=7&type=section&id=Balance%20Sheets) Balance Sheet Summary (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Cash and cash equivalents ($ thousands)** | $2,615 | $2,557 | | **Total current assets ($ thousands)** | $11,987 | $9,530 | | **Total assets ($ thousands)** | $12,610 | $10,255 | | **Total current liabilities ($ thousands)** | $21,441 | $20,777 | | **Total liabilities ($ thousands)** | $22,934 | $26,573 | | **Total stockholders' deficit ($ thousands)** | ($10,324) | ($16,318) | [Statement of Operations](index=9&type=section&id=Statement%20of%20Operations) Statement of Operations Summary (in thousands) | Account | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | **Revenues, net ($ thousands)** | $5,716 | $3,813 | | **Gross profit ($ thousands)** | $4,036 | $1,810 | | **Total operating expenses ($ thousands)** | $6,793 | $8,518 | | **Loss from operations ($ thousands)** | ($2,757) | ($6,708) | | **Unrealized gain on warrant liability ($ thousands)** | $4,203 | $1,687 | | **Net income (loss) ($ thousands)** | $1,284 | ($5,390) | | **Net income (loss) per share** | $0.28 | ($5.91) | [Reconciliation of GAAP to Non-GAAP Net Loss](index=10&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Net%20Loss) GAAP to Non-GAAP Reconciliation (in thousands) | Metric | Q1 2024 | Q4 2023 | Q1 2023 | | :--- | :--- | :--- | :--- | | **GAAP net income (loss) ($ thousands)** | $1,284 | ($4,467) | ($5,390) | | **Unrealized gain (loss) on warrant liability ($ thousands)** | $4,203 | ($130) | $1,687 | | **Non-GAAP net loss ($ thousands)** | ($2,919) | ($4,337) | ($7,077) | [About the Company and Product](index=3&type=section&id=About%20the%20Company%20and%20Product) Agile Therapeutics is a women's healthcare company focused on non-daily contraceptive options, featuring its flagship Twirla® once-weekly patch [About Agile Therapeutics, Inc.](index=3&type=section&id=About%20Agile%20Therapeutics%2C%20Inc.) - Agile Therapeutics is a women's healthcare company focused on providing contraceptive options that offer freedom from a daily pill without the commitment of a longer-acting method[8](index=8&type=chunk) [About Twirla®](index=3&type=section&id=About%20Twirla%C2%AE) - Twirla® is a once-weekly combined hormonal contraceptive patch indicated for women with a **BMI < 30 kg/m²**. It is contraindicated in women with a **BMI ≥ 30 kg/m²** and in women over 35 who smoke[9](index=9&type=chunk) [Supplemental Information](index=3&type=section&id=Supplemental%20Information) This section provides context for the report, defining prescription data, explaining non-GAAP financial measures, and including forward-looking statements [About Prescription Data](index=3&type=section&id=About%20Prescription%20Data) - The company sources its prescription data from Symphony Health Solutions. It believes factory sales more closely represent total demand for Twirla as not all non-retail channel data is captured by third-party services[10](index=10&type=chunk)[11](index=11&type=chunk) [Use of Non-GAAP Financial Measures](index=4&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) - The company uses **non-GAAP net loss**, which excludes recurring unrealized gains or losses from its warrant liability, to provide what it believes is a more useful measure for period-to-period comparisons of its business operations[12](index=12&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) - The press release contains forward-looking statements regarding the commercialization of Twirla®, market acceptance, future financing, and other strategic plans, which are subject to various risks and uncertainties[14](index=14&type=chunk)[16](index=16&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark if the registrant is not ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Matt Riley - Head of Investor Relations and Corporate Communications Al Altomari - Chairman and Chief Executive Officer Operator Good morning, and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2023 Financial Results Conference Call. Please note, today’s event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations. Please go ...

PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference ...

PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conferenc ...

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference ...